Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Cuts 30 Jobs in R&D Shift During Q3

NEW YORK (GenomeWeb News) – PerkinElmer reduced its headcount by 30 employees in the third quarter, the company said in a regulatory document this week.

PerkinElmer said that its management approved a plan during the quarter to shift some of its R&D resources into a newly opened Center for Innovation, resulting in the layoffs. It added in its quarterly financial document filed with the US Securities and Exchange Commission that all employees were notified of their termination by Sept. 29.

PerkinElmer recognized a $500,000 pre-tax restructuring charge in the Human Health segment related to the workforce reduction and said it anticipates the remaining payments of $400,000 for workforce reductions to be "substantially completed" by the end of the second quarter of 2014.

The most recent round of layoffs brings the total number of jobs that the Waltham, Mass.-based company has eliminated in 2013 to 357 through the first nine months of the year. It reduced its headcount by 62 in the first quarter and by 265 in the second quarter. The firm has approximately 7,500 employees worldwide.

PerkinElmer recently reported that its third quarter revenues increased 3 percent year over year to $524.3 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.